This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R-ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R-ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5-55.9) and 46.2 (95% CI: 38.9-53.5) months from diagnosis and initiation of first-line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5-40.3) vs 58.3 (95% CI: 53.8-62.9) months in high-risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2-38.0) vs 47.2 (95% CI: 43.4-51.0) months in Stage III vs Stage II patients (R-ISS; P < .001). In conclusion, IMWG and R-ISS risk stratification indices are applicable to patients with MM in a real-world setting.

1st Medical Department Clinical Department of Haematology of the 1st Faculty of Medicine General Teaching Hospital Charles University Prague Czech Republic

4th Department of Medicine Haematology Faculty of Medicine Charles University Hospital Hradec Králové Czech Republic

Department of Clinical Haematology Hospital in Havirov Havirov Czech Republic

Department of Clinical Hematology Hospital Ceske Budejovice Ceske Budejovice Czech Republic

Department of Haemato Oncology Faculty of Medicine University Hospital Ostrava University of Ostrava Ostrava Czech Republic

Department of Hemato Oncology Faculty of Medicine and Dentistry University Hospital Olomouc Palacky University Olomouc Czech Republic

Department of Hematology and Transfusion Medicine Hospital Pelhrimov Pelhrimov Czech Republic

Department of Hematology Hospital Liberec Liberec Czech Republic

Department of Hematology Hospital Novy Jicin Novy Jicin Czech Republic

Department of Hematology Hospital Opava Opava Czech Republic

Department of Internal Medicine and Hematology University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

Hematology and Oncology Department Charles University Hospital Pilsen Czech Republic

Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Palumbo A, Avet‐Loiseau H, Oliva S, et al. Revised International staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863‐2869. PubMed PMC

Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14:100‐113. PubMed

Badros AZ. In the age of novel therapies, what defines high‐risk multiple myeloma? J Natl Compr Cancer Netw. 2010;8(Suppl 1):S28‐S34. PubMed

Amodio N, D'Aquila P, Passarino G, Tassone P, Bellizzi D. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. Expert Opin Ther Targets. 2017;21:91‐101. PubMed

Rastgoo N, Abdi J, Hou J, Chang H. Role of epigenetics‐microRNA axis in drug resistance of multiple myeloma. J Hematol Oncol. 2017;10:121. PubMed PMC

Avet‐Loiseau H, Durie BGM, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013;27:711‐717. PubMed PMC

Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842‐854. PubMed

Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk‐Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360‐376. PubMed

Moreau P, Cavo M, Sonneveld P, et al. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front‐line autologous stem‐cell transplantation at high risk of early MM progression‐related death. J Clin Oncol. 2014;32:2173‐2180. PubMed PMC

Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412‐3420. PubMed

Chng WJ, Dispenzieri A, Chim C‐S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269‐277. PubMed

Brozova L, Schwarz D, Snabl I, et al. Czech Registry of monoclonal gammopathies ‐ technical solution. Data collection and visualisation. Klin Onkol. 2017;30:43‐50. PubMed

Radocha J, Pour L, Spicka I, et al. Registry of Monoclonal Gammopathies (RMG) in the Czech Republic. Blood. 2015;126:4514.

Samaras P, Blickenstorfer M, Haile SR, et al. Validation of prognostic factors and survival of patients with multiple myeloma in a real‐life autologous stem cell transplantation setting: a Swiss single centre experience. Swiss Med Wkly. 2011;141:w13203. PubMed

Jimenez‐Zepeda VH, Duggan P, Neri P, Rashid‐Kolvear F, Tay J, Bahlis NJ. Revised International staging system applied to real world multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2016;16:511‐518. PubMed

Kastritis E, Terpos E, Roussou M, et al. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica. 2017;102:593‐599. PubMed PMC

Terpos E, Katodritou E, Roussou M, et al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol. 2010;85:114‐119. PubMed

Gkotzamanidou M, Kastritis E, Gavriatopoulou MRMMM, et al. Increased serum lactate dehydrongenase should be included among the variables that define very‐high‐risk multiple myeloma. Clin Lymphoma Myeloma Leuk. 2011;11:409‐413. PubMed

Avet‐Loiseau H, Hulin C, Campion L, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol. 2013;31:2806‐2809. PubMed PMC

Jian Y, Chen X, Zhou H, et al. Prognostic impact of cytogenetic abnormalities in multiple myeloma: a retrospective analysis of 229 patients. Medicine (Baltimore). 2016;95:e3521. PubMed PMC

Merz M, Hielscher T, Seckinger A, et al. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Am J Hematol. 2016;91:E473‐E477. PubMed

An G, Li Z, Tai Y‐T, et al. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015;21:2148‐2156. PubMed

Lodé L, Eveillard M, Trichet V, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95:1973‐1976. PubMed PMC

Terebelo H, Srinivasan S, Narang M, et al. Recognition of early mortality in multiple myeloma by a prediction matrix. Am J Hematol. 2017;92:915‐923. PubMed PMC

Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR. Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real‐world practice. J Oncol Pract. 2015;11:491‐497. PubMed

Westgeest HM, Uyl‐de Groot CA, van Moorselaar RJA, et al. Differences in trial and real‐world populations in the Dutch Castration‐resistant Prostate Cancer Registry. Eur Urol Focus. 2016. 10.1016/j.euf.2016.09.008. PubMed DOI

Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335:91‐97. PubMed